Methotrexate for treating polymyalgia rheumatica: A meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Gwan Gyu | - |
dc.contributor.author | Lee, Young Ho | - |
dc.date.accessioned | 2021-11-20T11:40:35Z | - |
dc.date.available | 2021-11-20T11:40:35Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128109 | - |
dc.description.abstract | Objective: The objective of this study was to evaluate the efficacy and steroid-sparing effect of methotrexate (MTX) in patients with active polymyalgia rheumatica (PMR) undergoing prednisone therapy. Materials and methods: A meta-analysis of randomized controlled trial (RCT) was conducted to compare the efficacy and steroid-sparing effect of MTX with those of placebo in patients with PMR. Results: Four RCTs (97 patients and 97 controls) were used in this meta-analysis. The remission rate was significantly higher in the MTX group than in the placebo group (odds ratio (OR) = 5.699, 95% confidence interval (CI) = 2.401 - 13.53, p < 0.001). The relapse rate appeared lower in the MTX group than in the placebo group, albeit without significance (OR = 0.377, 95% CI = 0.093 - 1.526, p = 0.171). The cumulative steroid dosage was also significantly lower in the MTX group than in the placebo group (standard mean difference (SMD) = -1.636, 95% CI = -2.864 - 0.407, p = 0.009), which suggested the steroid-sparing role of MTX in PMR therapy. All studies showed the same pattern of SMDs in the cumulative steroid dose, but there was variability in the meta-analysis results for the cumulative steroid dose owing to the disparity in the extent of the effect. Conclusion: MTX in conjunction with prednisone was more successful than prednisone alone for treating PMR, and the use of MTX was correlated with a decreased average steroid dose. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.subject | MANAGEMENT | - |
dc.subject | ARTERITIS | - |
dc.title | Methotrexate for treating polymyalgia rheumatica: A meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.5414/CP203901 | - |
dc.identifier.scopusid | 2-s2.0-85106952694 | - |
dc.identifier.wosid | 000652062200003 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.59, no.5, pp.366 - 371 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 59 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 366 | - |
dc.citation.endPage | 371 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | ARTERITIS | - |
dc.subject.keywordAuthor | methotrexate | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | steroid-sparing effect | - |
dc.subject.keywordAuthor | polymyalgia rheumatica | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.